Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma

Monika Joshi, Monali Vasekar, Petros Grivas, Hamid Emamekhoo, Jo Ann Hsu, Vincent A. Miller, Philip J. Stephens, Siraj M. Ali, Jeffrey S. Ross, Junjia Zhu, Joshua Warrick, Joseph J. Drabick, Sheldon L. Holder, Matthew Kaag, Min Li, Sumanta Kumar Pal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Smoking has been linked to urothelial carcinoma (UC), but the implications on genomic profile and therapeutic response are poorly understood. To determine how smoking history impacts genomic profile and chemotherapy response, clinicopathologic data was collected for patients with metastatic UC (mUC) across 3 academic medical centers and comprehensive genomic profiling (CGP) was performed through a CLIA-certified lab. Unsupervised hierarchical clustering based on smoking status was used to categorize the frequency of genomic alterations (GAs) amongst current smokers (CS), ex-smokers (ES) and non-smokers (NS), and survival was compared in these subsets. Fisher's exact test identified significant associations between GAs and smoking status. Amongst 83 patients, 23%, 55% and 22% were CS, ES, and NS, respectively, and 95% of patients had stage IV disease. With a median follow up of 14.4 months, the median overall survival (OS) was significantly higher in NS and ES (combined) as compared to CS (51.6 vs 15.6 months; P = 0.04). Of 315 cancer-related genes and 31 genes often related to rearrangement tested, heatmaps show some variations amongst the subsets. GAs in NSD1 were more frequent in CS as compared to other groups (P < 0.001). CS status negatively impacts OS in patients with mUC and is associated with genomic alterations that could have therapeutic implications.

Original languageEnglish (US)
Pages (from-to)52442-52449
Number of pages8
JournalOncotarget
Volume7
Issue number32
DOIs
StatePublished - Aug 1 2016

Fingerprint

Smoking
Carcinoma
Drug Therapy
Survival
Neoplasm Genes
Cluster Analysis
History
Therapeutics
Genes

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Joshi, Monika ; Vasekar, Monali ; Grivas, Petros ; Emamekhoo, Hamid ; Hsu, Jo Ann ; Miller, Vincent A. ; Stephens, Philip J. ; Ali, Siraj M. ; Ross, Jeffrey S. ; Zhu, Junjia ; Warrick, Joshua ; Drabick, Joseph J. ; Holder, Sheldon L. ; Kaag, Matthew ; Li, Min ; Pal, Sumanta Kumar. / Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. In: Oncotarget. 2016 ; Vol. 7, No. 32. pp. 52442-52449.
@article{0807464a0b9b4ff8836b6709d5181b08,
title = "Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma",
abstract = "Smoking has been linked to urothelial carcinoma (UC), but the implications on genomic profile and therapeutic response are poorly understood. To determine how smoking history impacts genomic profile and chemotherapy response, clinicopathologic data was collected for patients with metastatic UC (mUC) across 3 academic medical centers and comprehensive genomic profiling (CGP) was performed through a CLIA-certified lab. Unsupervised hierarchical clustering based on smoking status was used to categorize the frequency of genomic alterations (GAs) amongst current smokers (CS), ex-smokers (ES) and non-smokers (NS), and survival was compared in these subsets. Fisher's exact test identified significant associations between GAs and smoking status. Amongst 83 patients, 23{\%}, 55{\%} and 22{\%} were CS, ES, and NS, respectively, and 95{\%} of patients had stage IV disease. With a median follow up of 14.4 months, the median overall survival (OS) was significantly higher in NS and ES (combined) as compared to CS (51.6 vs 15.6 months; P = 0.04). Of 315 cancer-related genes and 31 genes often related to rearrangement tested, heatmaps show some variations amongst the subsets. GAs in NSD1 were more frequent in CS as compared to other groups (P < 0.001). CS status negatively impacts OS in patients with mUC and is associated with genomic alterations that could have therapeutic implications.",
author = "Monika Joshi and Monali Vasekar and Petros Grivas and Hamid Emamekhoo and Hsu, {Jo Ann} and Miller, {Vincent A.} and Stephens, {Philip J.} and Ali, {Siraj M.} and Ross, {Jeffrey S.} and Junjia Zhu and Joshua Warrick and Drabick, {Joseph J.} and Holder, {Sheldon L.} and Matthew Kaag and Min Li and Pal, {Sumanta Kumar}",
year = "2016",
month = "8",
day = "1",
doi = "10.18632/oncotarget.9449",
language = "English (US)",
volume = "7",
pages = "52442--52449",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "32",

}

Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. / Joshi, Monika; Vasekar, Monali; Grivas, Petros; Emamekhoo, Hamid; Hsu, Jo Ann; Miller, Vincent A.; Stephens, Philip J.; Ali, Siraj M.; Ross, Jeffrey S.; Zhu, Junjia; Warrick, Joshua; Drabick, Joseph J.; Holder, Sheldon L.; Kaag, Matthew; Li, Min; Pal, Sumanta Kumar.

In: Oncotarget, Vol. 7, No. 32, 01.08.2016, p. 52442-52449.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma

AU - Joshi, Monika

AU - Vasekar, Monali

AU - Grivas, Petros

AU - Emamekhoo, Hamid

AU - Hsu, Jo Ann

AU - Miller, Vincent A.

AU - Stephens, Philip J.

AU - Ali, Siraj M.

AU - Ross, Jeffrey S.

AU - Zhu, Junjia

AU - Warrick, Joshua

AU - Drabick, Joseph J.

AU - Holder, Sheldon L.

AU - Kaag, Matthew

AU - Li, Min

AU - Pal, Sumanta Kumar

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Smoking has been linked to urothelial carcinoma (UC), but the implications on genomic profile and therapeutic response are poorly understood. To determine how smoking history impacts genomic profile and chemotherapy response, clinicopathologic data was collected for patients with metastatic UC (mUC) across 3 academic medical centers and comprehensive genomic profiling (CGP) was performed through a CLIA-certified lab. Unsupervised hierarchical clustering based on smoking status was used to categorize the frequency of genomic alterations (GAs) amongst current smokers (CS), ex-smokers (ES) and non-smokers (NS), and survival was compared in these subsets. Fisher's exact test identified significant associations between GAs and smoking status. Amongst 83 patients, 23%, 55% and 22% were CS, ES, and NS, respectively, and 95% of patients had stage IV disease. With a median follow up of 14.4 months, the median overall survival (OS) was significantly higher in NS and ES (combined) as compared to CS (51.6 vs 15.6 months; P = 0.04). Of 315 cancer-related genes and 31 genes often related to rearrangement tested, heatmaps show some variations amongst the subsets. GAs in NSD1 were more frequent in CS as compared to other groups (P < 0.001). CS status negatively impacts OS in patients with mUC and is associated with genomic alterations that could have therapeutic implications.

AB - Smoking has been linked to urothelial carcinoma (UC), but the implications on genomic profile and therapeutic response are poorly understood. To determine how smoking history impacts genomic profile and chemotherapy response, clinicopathologic data was collected for patients with metastatic UC (mUC) across 3 academic medical centers and comprehensive genomic profiling (CGP) was performed through a CLIA-certified lab. Unsupervised hierarchical clustering based on smoking status was used to categorize the frequency of genomic alterations (GAs) amongst current smokers (CS), ex-smokers (ES) and non-smokers (NS), and survival was compared in these subsets. Fisher's exact test identified significant associations between GAs and smoking status. Amongst 83 patients, 23%, 55% and 22% were CS, ES, and NS, respectively, and 95% of patients had stage IV disease. With a median follow up of 14.4 months, the median overall survival (OS) was significantly higher in NS and ES (combined) as compared to CS (51.6 vs 15.6 months; P = 0.04). Of 315 cancer-related genes and 31 genes often related to rearrangement tested, heatmaps show some variations amongst the subsets. GAs in NSD1 were more frequent in CS as compared to other groups (P < 0.001). CS status negatively impacts OS in patients with mUC and is associated with genomic alterations that could have therapeutic implications.

UR - http://www.scopus.com/inward/record.url?scp=84982298226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982298226&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9449

DO - 10.18632/oncotarget.9449

M3 - Article

C2 - 27213592

AN - SCOPUS:84982298226

VL - 7

SP - 52442

EP - 52449

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 32

ER -